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the context of a prospective trial, we cannot exclude the possibility
of multiple vaccine interactions; however, it appears unlikely at this
time.
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A Simple, Inexpensive, Rapid,
and Accurate Preclinical
Model for In-Stent Restenosis
With great interest we read the recent review by Schwartz et al. (1)
regarding preclinical animal restenosis models. Detailed descrip-
tions of the current available animal restenosis models, the patho-
physiology of in-stent restenosis (ISR), and the usefulness of
animal restenosis models to predict clinical outcomes are pre-
sented. In the final remarks it is concluded that preclinical models
are important but imperfect standards. A simple, inexpensive,
rapid, and accurate preclinical model would be useful. However, in
their description of available restenosis models, Schwartz et al. (1)
overlooked two important and recently developed animal models
of ISR. In these models, stents are implanted in the carotid artery
(2) or in the abdominal aorta (3) of the rat. Pathophysiological
processes of neoinitmal formation, such as thrombus formation,
inflammation, and smooth muscle cell proliferation, evolve in an
identical manner as seen in the rabbit iliac and pig coronary artery
models. Moreover, in the rat abdominal aorta model, a positive
correlation is found between the mean injury score and the
neointimal area (2,3).
Rat ISR models enable thorough pathophysiological studies, as
many antibodies to cellular proteins are available in the rat as
compared to rabbits and pigs. By elucidation of the pathophysiol-
ogy of ISR, more purposeful experiments to prevent ISR can be
carried out. Rat models of ISR could provide important indications
for the development of new anti-restenotic strategies (3). Gener-
ally, rat studies are preferable over rabbit or pig studies; only
mainstream surgical equipment is required, animal facilities have
large housing capacity for rats, and the costs for purchase are low.
Discrepancies between efficacy of anti-restenotic agents in
preclinical and clinical studies have caused skepticism about the rat
carotid artery model. For rat stent models this skepticism should be
tempered, because differences in pathophysiological mechanisms
between neointimal formation after balloon dilation alone and
stent implantation are evident. Furthermore, rapamycin-eluting
stents have been shown to inhibit neointimal formation in the rat
abdominal aorta, a clear relation between preclinical and clinical
outcomes in this model (3). In addition, these rat models enable
stent research in transgenic diabetic and hypertensive strains. This
offers a truer reflection of clinical settings in preclinical experi-
ments, and might result in a better prediction of efficacy of
anti-restenotic agents in clinical trials (2,3).
In conclusion, rat models are simple, inexpensive, rapid, and
accurate preclinical models for ISR.
*Bas Langeveld, MD
Wiek H. Van Gilst, PhD
Felix Zijlstra, MD, PhD
*Department of Clinical Pharmacology
University Hospital Groningen
Antonius Deusinglaan 1
9713 AV Groningen
the Netherlands
Email: be.langeveld@med.rug.nl
doi:10.1016/j.jacc.2005.01.027
REFERENCES
1. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models
and drug-eluting stents: still important, still much to learn. J Am Coll
Cardiol 2004;44:1373–85.
2. Finn AV, Gold HK, Tang A, et al. A novel rat model of carotid artery
stenting for the understanding of restenosis in metabolic diseases. J Vasc
Res 2002;39:414–25.
3. Langeveld B, Roks AJ, Tio RA, et al. Rat abdominal aorta stenting: a
new and reliable small animal model for in-stent restenosis. J Vasc Res
2004;41:377–86.
REPLY
We read with interest the comments of Dr. Langeveld and
colleagues concerning our recent review of preclinical restenosis
models (1). These investigators write that stenting the rat carotid
or abdominal artery provides a “simple, inexpensive, rapid, and
accurate preclinical model for in-stent restenosis.” We have several
comments in response regarding the utility of the rat model.
A useful in-stent restenosis animal model should accurately
predict: 1) safety, 2) efficacy, and 3) pathophysiologic mechanisms.
These are addressed as follows.
Safety. The major safety issues for stents are thrombosis (acute
or subacute) and neointimal thickening causing luminal stenosis.
Although the rat model sometimes induces stent thrombosis, it
does so to a lesser extent than the porcine and rabbit models. Total
occlusion and severe stent stenosis do not generally occur in the rat
model.
Efficacy. Rat carotid restenosis models were abandoned years ago
because virtually all therapies that were tested and effective in rats
later proved ineffective in patients. Such studies included
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angiotensin-converting enzyme inhibition, heparin, and other
anticoagulants, antiplatelet therapies, and corticosteroids. Much
expense, time, and energy-conducting clinical trials were expended
based on inaccurate results from rat models. This may occur as
stent efficacy is determined by neointimal inhibition and preven-
tion of negative remodeling. Rat vessels may develop enough
neointima to cause arterial narrowing following stenting, but they
do not appear to exhibit remodeling. Rat models of diabetes and
hypertension exist that could theoretically test different aspects of
human disease. Drug-eluting stents have been deployed in rat
carotid arteries, and we are awaiting the outcome of these studies
(R. Virmani, unpublished data, August 2005). Much current effort
is directed toward establishing efficacy parameters in the pig and
rabbit model, with promising early results by investigators such as
Touchard et al. (personal communication, November 2005) or
Finn et al. (personal communication, September 2005).
Simplicity, expense, rapidity. Stenting rat carotid arteries is as
simple as stenting porcine or rabbit vessels. Whether the rat model
is truly cheaper than the rabbit or porcine model is unclear. The
purchase costs and per diem housing are higher with pigs than
with rabbits or rats. This is partially overcome though by the ability
to place three or sometimes four stents in a single pig, and two in
the rabbit carotid or three to four stents in the rabbit aorta.
The porcine model offers the advantage of being an excellent
coronary artery model for testing stent, guidewire, and catheter
performance in arterial beds with size, shape, curvature, and
tortuosity similar to humans. Flow dynamics in a small, noncoro-
nary vessel such as in the rat differ dramatically from patients, with
different shear and boundary layer flow. These may be important in
the era of drug-eluting stents where elution is dependent on flow
parameters. Elution studies have been performed in the rabbit iliac
arteries and are similar to those in the pig (A. Finn, personal
communication, September 2005).
Importantly, the major costs of preclinical restenosis studies
relate to surgical time, histopathologic stent processing (requiring
plastic embedding), and careful histomorphometric measurement.
Using a rat model for this step is thus no simpler, and it saves
neither time nor expense compared to rabbits or pigs.
Finally, it is certainly true that the available antibodies and
knowledge of proteins and genes are greater for rats and mice
compared to rabbits and pigs. However, given the desire by the
interventionalist and the Food and Drug Administration to
achieve parallel clinical trial results, elucidation of vascular re-
sponse mechanisms in rodents may have limited translational
value, although of scientific merit and interest.
Until stented rat models are validated against clinical trials for
providing accurate results, we are hesitant to recommend this
strategy, and we must continue to question scientifically the
wisdom of their use in translational vascular research. Hence, large
animal models continue to be the standard. In the meantime,
vigorous scientific debate and discussion about animal models in
vascular biology is both welcomed and exciting. There is no doubt
that for safety studies we are limited to the pig coronary artery
model, which also assesses the distal myocardial bed for ischemia
and emboli.
Thus, we look forward to future scientific and validation studies
of the stented rat model by Dr. Langeveld and others, and we
thank them for their comments.
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